|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
|
DK2300035T3
(en)
|
2008-06-17 |
2015-11-16 |
Univ Indiana Res & Tech Corp |
Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
|
|
CN102325539A
(zh)
|
2008-12-19 |
2012-01-18 |
印第安纳大学研究及科技有限公司 |
基于酰胺的胰高血糖素超家族肽前药
|
|
CN102300580A
(zh)
|
2008-12-19 |
2011-12-28 |
印第安纳大学研究及科技有限公司 |
二肽连接的药剂
|
|
WO2010148089A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
EP2512518A1
(en)
|
2009-12-16 |
2012-10-24 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
EP2588127A4
(en)
|
2010-06-24 |
2014-06-11 |
Univ Indiana Res & Tech Corp |
DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
|
|
RU2580317C2
(ru)
|
2010-06-24 |
2016-04-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
SG191252A1
(en)
|
2010-12-22 |
2013-07-31 |
Marcadia Biotech Inc |
Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
|
|
WO2012167744A1
(en)
|
2011-06-10 |
2012-12-13 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
RU2014117678A
(ru)
*
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
|
EP3542790B1
(en)
|
2012-03-22 |
2023-09-13 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
HRP20180936T1
(hr)
|
2012-06-21 |
2018-12-14 |
Indiana University Research And Technology Corporation |
Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
CN105324125A
(zh)
|
2013-03-15 |
2016-02-10 |
印第安纳大学研究及科技有限公司 |
具有长效的前体药物
|
|
JP6672140B2
(ja)
|
2013-05-02 |
2020-03-25 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１化合物の経口投薬
|
|
LT3004155T
(lt)
|
2013-05-28 |
2021-12-27 |
Takeda Pharmaceutical Company Limited |
Peptidų junginys
|
|
HK1226084A1
(zh)
|
2013-08-16 |
2017-09-22 |
Medimmune Limited |
用於治疗糖尿病的gip和glp-1受体双重激动剂
|
|
WO2015035419A1
(en)
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
GB2528436A
(en)
|
2014-07-15 |
2016-01-27 |
Lancaster Univ Business Entpr Ltd |
Treatment of neurological diseases
|
|
WO2016049174A1
(en)
|
2014-09-24 |
2016-03-31 |
Indiana University Research And Technology Corporation |
Lipidated amide-based insulin prodrugs
|
|
WO2016077220A1
(en)
|
2014-11-10 |
2016-05-19 |
Mb2 Llc |
Gip/glp-1 co-agonist peptides for human administration
|
|
JP2018012644A
(ja)
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
JO3575B1
(ar)
|
2015-01-09 |
2020-07-05 |
Lilly Co Eli |
مركبات مساعد مشترك من gip وglp-1
|
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
|
US20170112897A1
(en)
|
2015-10-23 |
2017-04-27 |
Cedars-Sinai Medical Center |
Methods for treating brain insulin resistance
|
|
WO2017204219A1
(ja)
|
2016-05-24 |
2017-11-30 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
GB201620611D0
(en)
|
2016-12-05 |
2017-01-18 |
Univ Of Lancaster |
Treatment of neurological diseases
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
|
KR102379958B1
(ko)
|
2018-05-04 |
2022-04-01 |
노보 노르디스크 에이/에스 |
Gip 유도체 및 이의 용도
|
|
CN120754229A
(zh)
|
2018-07-23 |
2025-10-10 |
伊莱利利公司 |
使用gip/glp1共激动剂用于治疗的方法
|
|
CN112469731B
(zh)
|
2018-07-23 |
2024-11-29 |
伊莱利利公司 |
Gip/glp1共激动剂化合物
|
|
EP3826662B9
(en)
|
2018-07-23 |
2025-02-19 |
Eli Lilly and Company |
Method of using a gip/glp1 co-agonist for diabetes
|
|
MX2021012277A
(es)
*
|
2019-04-11 |
2021-11-12 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Agonista multireceptor y uso medico del mismo.
|
|
CN110642935A
(zh)
|
2019-09-25 |
2020-01-03 |
成都奥达生物科技有限公司 |
一种替瑞帕肽类似物
|
|
CN110684082B
(zh)
|
2019-10-08 |
2021-12-10 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
|
|
MX2023000303A
(es)
*
|
2020-07-22 |
2023-02-09 |
Novo Nordisk As |
Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
|